In the first nine months of 2010, the company posted a net profit of RON2.9 million.

Farmaceutica Remedia said total sales rose 11.4% to RON144.6 million in January to September, from RON130 million in the year-earlier period.

The company reported overall revenue of RON146.7 million, up 11.4% on the year, while total costs were up 10.6% to RON141.6 million.

Farmaceutica estimates total revenue of RON224.02 million in 2011, up 21.2% on the year, while overall costs are expected to increase at a similar pace, to RON220.28 million.

Managing board president Valentin Norbert Tarus holds 66.05% of the company’s shares, while Lutz Stache controls a stake of some 16.5%.

On the Bucharest bourse Tuesday, Farmaceutica Remedia closed up 2.56% at RON0.2 a share. (EUR1=RON4.3487)